Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Earnings Results, Misses Expectations By $0.06 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS) released its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06), Zacks reports.

Corvus Pharmaceuticals Stock Performance

CRVS stock traded down $0.27 during midday trading on Tuesday, reaching $3.98. 959,178 shares of the company’s stock traded hands, compared to its average volume of 564,653. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00. The company has a 50-day moving average price of $4.72 and a two-hundred day moving average price of $6.10. The firm has a market capitalization of $255.74 million, a PE ratio of -4.28 and a beta of 0.91.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.38.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.